Sorrento Therapeutics Inc (SRNE)

[dia76ca]

MOST small biotechs have been hammered in the past year! However Sorrento has three sources of revenue to fuel a turnaround. COVISTIX, ABIVERTINIB and SEMDEXA are each blockbusters.
1. COVISTIX revenue is ramping up each quarter. Q4 2021 will show some revenue. Q1 2022 will show large revenue. Production near term will be 30 million monthly increasing to 100+ million monthly by year end.
2. ABIVERTINIB "teaser " deal will bring in Multi-billions in up-front, milestone and royalty revenues. It is over 8 months since Sorrento stated that it was seeking a partnership. That is about the timeframe expected for a large partnership!
3. SEMDEXA non-opioid sciatica pain sales projections of $5-10 billion in the US alone with an additional 50-200% increase with label expansions. They have Fast Track status and are applying for Breakthrough Designation. FDA must respond within 60 days of application. A sales crew is already in the field. Revenue stream could begin Mid-2022!

And look for news about COVI-MSC, COVISHIELD, Mpro oral antiviral and VIREX
viral and cancer tests! A lot of news and a lot of revenue in 2022!